Cara Therapeutics

$19.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.56 (-2.83%) Today

$0.00 (0.00%) As of 1:00 PM UTC after-hours

Why Robinhood?

You can buy or sell CARA and other stocks, options, and ETFs commission-free!

About CARA

Cara Therapeutics, Inc. Common Stock, also called Cara Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT. The listed name for CARA is Cara Therapeutics, Inc. Common Stock.

CEO

Derek T. Chalmers

Employees

Headquarters

Stamford, Connecticut

Founded

2004

Market Cap

953.47M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

700.45K

High Today

$19.91

Low Today

$18.83

Open Price

$19.33

Volume

389.24K

52 Week High

$22.60

52 Week Low

$8.88

CARA News

BenzingaFeb 24

Preview: Cara Therapeutics's Earnings

On Thursday, February 25, Cara Therapeutics (NASDAQ:CARA) will release its latest earnings report. Decipher the announcement with Benzinga's help. What Are Ear

Analyst Ratings

88%

of 8 ratings

Buy

88%

Hold

13%

Sell

CARA Earnings

-$0.74

$0.04

$0.81

$1.59

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

$0.36 per share

Actual

$1.59 per share

Replay Earnings Call